analyzed the prognosis of 72 HR+/HER2- advanced breast cancer patients who received first-line ET, and the study showed that the OS and PFS of HER2-low patients were lower than those of HER2-zero patients (53). This evidence concerns the gene ERBB2 and breast cancer.